NCT02925000: Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

NCT02925000
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions: Patients with active unstable untreated brain metastases- see trial for details; Patients who have received more than 5 prior lines of cytotoxic therapies
https://ClinicalTrials.gov/show/NCT02925000

Comments are closed.

Up ↑